PFE vs AMGN — which stock performed better?

Pfizer Inc. (PFE) versus Amgen Inc. (AMGN), Health Care, on 2026-10-06.

Result

Amgen Inc. (AMGN) performed better on 2026-10-06. PFE moved -0.110%, AMGN moved 0.060%.

Why these two companies

Pfizer is in focus after reporting late-stage immunology trial data on an alopecia medicine and deepening its obesity push through a newly completed metabolic-focused acquisition, headlines that broke on Monday, October 5, 2026. That obesity build-out puts Pfizer squarely in competition with Amgen, whose own injectable obesity candidate MariTide is advancing through Phase 3 trials as both companies chase a slice of the GLP-1 market currently led by Eli Lilly and Novo Nordisk. Both stocks also happen to report quarterly earnings on the very same date, November 3, 2026, adding a second layer to the comparison.

The research

Pfizer makes a wide range of medicines and vaccines, from cancer treatments to shots, and is now also pushing into weight-loss drugs after buying a company that was developing one. Amgen makes biotech medicines for conditions like high cholesterol and bone disease, and is also building a weight-loss drug of its own that it hopes patients will only need to take a few times a year.

One reason to like Pfizer is its very high dividend payment and a stock price that some analysts think is undervalued compared to its turnaround potential. One reason to like Amgen is that its sales have been growing faster lately, and its weight-loss drug candidate is further along in testing stages that could lead to approval.

Something to keep in mind about Pfizer is that several of its older, big-selling drugs are losing exclusivity or still recovering from the drop-off in COVID-related sales. Something to keep in mind about Amgen is that its stock is already priced for a lot of future success, so any disappointing news on its pipeline could hit the share price harder.

Both companies will share quarterly results on the same day in early November, so this matchup is as much about today's weight-loss drug news as it is about each company's overall business health.